Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Prostate Cancer | Current Treatment: Physician Insights | US | 2023

Login to access report north_east
Contact sales account_box

Hormonal therapy is the cornerstone of drug treatment for prostate cancer in all patient populations. Abiraterone and Xtandi (Pfizer / Astellas Pharma) dominate the metastatic castrate-resistant prostate cancer (mCRPC) market and account for sizable market shares in the metastatic hormone-sensitive prostate cancer (mHSPC) setting. They compete with other next-generation hormonal therapies like Erleada (Janssen) and Nubeqa (Bayer HealthCare), two brands initially approved for nonmetastatic castrate-resistant prostate cancer (nmCRPC). The PSMA-targeted radioligand therapy Pluvicto (Novartis), which the FDA approved in March 2022, is having an impact on the treatment of mCRPC. The PARP inhibitors Lynparza (AstraZeneca) and Rubraca (Clovis Oncology) offer other biomarker-driven options for mCRPC treatment, and Xofigo (Bayer HealthCare) and Jevtana (Sanofi) are other nonhormonal treatment options for mCRPC, particularly in later lines.

Questions Answered

  • What are the drug-treatment rates across clinically and commercially relevant prostate cancer patient populations?
  • What is the uptake of the PSMA radioligand therapy Pluvicto in mCRPC to date?
  • What are the patient shares of key therapies in commercially relevant prostate cancer patient populations?
  • What are the main drivers of and obstacles to the uptake of current therapies in select hormone-sensitive and castrate-resistant patient segments?

Product Description

Current Treatment: Physician Insights provides physician insights ontreatment dynamics, prescribing behavior, and drivers of brand useso that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Markets covered: United States

Primary research: Survey of 100 medical oncologists and urologists (50 of each specialty) in the United States fielded in May 2023.

Key drugs covered: Abiraterone, Xtandi, Erleada, Nubeqa, Orgovyx, Pluvicto, Provenge, Xofigo, Jevtana, Lynparza, Rubraca, others

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Vitiligo – Current Treatment – Treatment Algorithms: Claims Data Analysis – Vitiligo (US)
Vitiligo is a chronic skin depigmentation disorder characterized by the destruction or functional loss of melanocytes. Given its visible manifestations, the disease is associated with a substantial…
north_east
Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Ulcerative Colitis – Unmet Need – Unmet Need – Moderate to Severe Ulcerative Colitis (US/EU)
The treatment landscape for ulcerative colitis (UC) is rapidly evolving. TNF-alpha inhibitors (Johnson & Johnson Innovative Medicine’s Remicade, AbbVie’s Humira), a CAM inhibitor (Takeda’s…
north_east
Report
Alzheimer’s Disease – Geographic Focus: China – China In-Depth – Alzheimer’s Disease
Alzheimer’s disease (AD) is a progressive and irreversible neurodegenerative disorder characterized by cognitive decline, memory impairment, and loss of functional independence. In China, current…
north_east
Report
Squamous Cell Carcinoma of the Head and Neck – Geographic Focus: China – China In-Depth – Squamous Cell Carcinoma of the Head and Neck
China’s SCCHN market is undergoing rapid transformation, driven by the expanding use of systemic therapies beyond traditional surgery and radiotherapy. Current treatment options include…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east